Innovative 3D-Printed Biodressing Shows Promise for Treating Chronic Wounds and Severe Burns

In Brazil, the healthcare sector is on the brink of a significant advancement with the development of a pioneering 3D-printed biodressing designed for the treatment of chronic wounds and severe burns. This innovative product, created by a startup at the Supera Innovation and Technology Park in Ribeirão Preto, integrates human umbilical cord stem cells, potentially revolutionizing patient care in this area.

The startup, known as In Situ, is gearing up to showcase its groundbreaking technology at the upcoming international VivaTech fair in Paris, one of Europe's foremost startup and technology events, scheduled for June 11-14. The event presents a valuable opportunity for the company to explore the European market for advanced therapy products, where several similar products are already registered.

The biodressing, named Mensencure, is constructed from hydrogel and is embedded with mesenchymal cells. These cells are known for their ability to secrete various bioactive molecules that play critical roles in the healing process. Such molecules include cytokines and growth factors that facilitate immunomodulation, promote angiogenesis (the formation of new blood vessels), and enhance the quality of scar tissue.

What sets Mensencure apart is its smart functionality; the biodressing contains living cells capable of interpreting signals from skin injuries. These cells can respond by releasing the necessary cytokines and growth factors in accordance with the specific needs of the damaged tissue. Unlike traditional products that merely cover wounds or target specific healing phases, Mensencure is engineered to support multiple stages of skin recovery.

One of the primary applications of this biodressing is for treating skin lesions in individuals with type 1 diabetes, a demographic that often struggles with wound healing. Elevated blood sugar levels associated with uncontrolled diabetes can significantly impede various stages of the healing process, leading to prolonged recovery times. The innovative biodressing aims to assist these patients whose wounds often remain unhealed for extended periods.

Initially, In Situ plans to focus on utilizing the biodressing for patients suffering from pressure injuries, commonly referred to as bedsores. However, before it can be widely adopted, the product must undergo clinical trials. If successful, the company intends to seek approval from the National Health Surveillance Agency (ANVISA), the regulatory authority overseeing health treatments and technologies in Brazil.

The team is currently navigating a crucial phase in the production process, ensuring that both the cells and the biodressing are manufactured in compliance with Good Manufacturing Practices (GMP). This adherence to stringent standards is essential for obtaining the necessary authorization from ANVISA to initiate clinical studies.

In Situ aims not only to develop Mensencure but also to expand its product offerings based on this advanced technology within its laboratory. The company aspires to transition from research to market, distinguishing itself from many biotechnology firms that do not pursue commercial avenues.